New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
07:19 EDTMYL, MRKMerck, Mylan CEOs plan to not leave U.S., Bloomberg says
Merck (MRK) CEO Ken Frazier and Mylan (MYL) CEO Heather Bresch said that despite many of their rivals departing the U.S., they won't leave the country if possible, according to Bloomberg, citing comments from both CEOs in separate interviews. Reference Link
News For MRK;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
08:46 EDTMYLMylan buyout below $95/share favorable for Teva, says Leerink
Subscribe for More Information
08:20 EDTMYLMylan’s Piatt was developer at land where company built headquarters, WSJ says
Mylan’s vice chairman and lead independent director Rodney Piatt served as the main developer of the company’s Pittsburgh office park where it built new headquarters, the Wall Street Journal reports, citing property records. Just a day before Mylan unveiled plans to build its new headquarters in an office park near Pittsburgh in December 2013, a company owned by Mylan vice chairman and lead independent director Rodney Piatt sold a 7-acre site for $1 to an entity owned by Andrew Miller, a business partner in Southpointe II, the report says. The firm sold the same land to Mylan for $2.9M later that same day, the report says. Mylan says there was no need to disclosed Piatt’s connection to the real estate project since he and the company avoided any direct dealings with each other, the Wall Street Journal reports. The records obtained by the Journal show that a similar transaction occurred in May, when Mylan paid $9.2M to buy an adjacent 11 acres from Miller, whose firm previously purchased the land for $10 from a company partly owned by Piatt. Reference Link
07:08 EDTMRKAllergan to acquire rights to Merck's CGRP for $250M
Subscribe for More Information
July 6, 2015
13:44 EDTMYLMylan calls active after report of new Teva bid
Subscribe for More Information
12:31 EDTMYLTeva to bump bid for Mylan up to $86-$88 per share, Bloomberg says
Teva (TEVA) plans to raise its takeover bid for Mylan (MYL) to $86 to $88 per share from the $82 per share it offered in April, reported Bloomberg, citing people with knowledge of the matter, who said the sweetened bid could be announced as soon as this week. Shares of Mylan are up 0.8% to $70.69 following the report, while Teva shares are up 0.3% to $61.74. Reference Link
12:22 EDTMYLMylan jumps after Bloomberg report of new Teva bid
Subscribe for More Information
12:18 EDTMYLTeva planning to raise Mylan bid to $86-$88/share, Bloomberg reports
Subscribe for More Information
July 2, 2015
09:50 EDTMYLThe Medicines Co. drops 3.2% to $27.43 in early trading
Subscribe for More Information
July 1, 2015
08:01 EDTMYLTeva CEO: Pharma industry undergoing “very big shakeup,” Globes reports
Subscribe for More Information
June 30, 2015
08:27 EDTMYLPerrigo deal for Roxane would make Mylan fight harder, says Citi
Subscribe for More Information
June 29, 2015
08:39 EDTMRKMerck says Phase 3 Emend data shows it provides 'greater protection' from nausea
Merck announced results from a Phase 3 study investigating the safety and efficacy of single-dose Emend for Injection, Merck’s substance P/neurokinin receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting, or CINV, in adult cancer patients receiving moderately emetogenic chemotherapy, or MEC. In the study, the first to evaluate an intravenous NK-1 receptor antagonist for the prevention of CINV associated with MEC, the single-dose Emend for Injection regimen provided greater protection from nausea and vomiting following administration of chemotherapy versus an active control of placebo with other anti-vomiting medicines. These data were presented in an oral session at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on “Supportive Care in Cancer” in Copenhagen.
June 25, 2015
12:52 EDTMYLEU to decide by July 29 on Mylan's bid for Perrigo, Reuters reports
Subscribe for More Information
June 24, 2015
09:07 EDTMRKCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use